Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bermekimab
- Development stage
- Phase 3
- Lead developer
- Janssen Research & Development
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
Bermekimab is a fully human IgG1 monoclonal antibody that specifically targets and neutralizes interleukin 1 alpha (IL-1α), a pro-inflammatory cytokine implicated in various inflammatory and neoplastic diseases. By inhibiting IL-1α signaling, bermekimab reduces inflammation and modulates immune responses. It was originally developed by XBiotech and has been investigated for multiple indications including atopic dermatitis, systemic scleroderma (systemic sclerosis), colorectal cancer with cachexia, hidradenitis suppurativa, acne vulgaris, plaque psoriasis, type 2 diabetes mellitus, rheumatoid arthritis and several other inflammatory or neoplastic conditions. The drug has undergone clinical trials up to phase III in some indications but development has been discontinued or terminated for many of them[2][5][7][8].
- Brand names
- Xilonix
- Other names
- HutruoHuman IGG1 monoclonal antibody specific for human interleukin-1 alpha
02
Targets
IL1A (Interleukin 1 alpha)
Beyond the preview
Go deeper on bermekimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bermekimab.